Publications

Search our bibliography using the filters on the right-hand side.

Displaying 201 through 250 of 697 publications.

Zhang Y, Herring W. The impact of alternative weighting methodologies on cross-indication value-based pricing estimates. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S289. doi: 10.1016/j.jval.2020.04.094

Sutphin J, DiSantostefano R, Leach CA, Hauber B, Mansfield C. Preferences, optimism, and numeracy: an exploration into the use of psychological patient-reported outcome instruments in a preference survey. Presented at the 2020 ISPOR Virtual Conference; May 19, 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S328. doi: 10.1016/j.jval.2020.04.094

Sutphin J, Mansfield C, DiSantostefano R, Klein K, Boeri M. Getting the most out of latent-class analysis in modeling preferences for an interception treatment in Type 1 diabetes. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S125. doi: 10.1016/j.jval.2020.04.371

Gnanasakthy A, Barrett A, D'Alessio D, Norcross L. Review of patient and clinician global assessments in PRO labeling (2017-2019). Poster presented at the ISPOR Virtual 2020 Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S299. doi: 10.1016/j.jval.2020.04.094

Thach A, Sutphin J, Coulter J, Mansfield C. Preferences for on-demand treatments for Parkinson's disease–related "OFF" episodes: a discrete-choice experiment. Presented at the 2020 ISPOR Virtual Conference; May 18, 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S325. doi: 10.1016/j.jval.2020.04.094

La EM, Talbird SE, Brogan AJ, Davis AE. Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S174. doi: 10.1016/j.jval.2020.04.371

Yi Z, Mauskopf J, Herring W, Graham J. Challenges in estimating eligible population size in budget-impact analyses for new health care technologies. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S288. doi: 10.1016/j.jval.2020.04.371

Pearce AM, Mulhern BJ, Watson V, Viney RC. How are debriefing questions used in health discrete choice experiments? An online survey. Value Health. 2020 Mar;23(3):289-93. doi: 10.1016/j.jval.2019.10.001

Reed SD, McLeod L. Moving beyond the tip of the iceberg to incorporate patients' perspectives and outcomes in the medical device regulatory process. Value Health. 2020 Mar;23(3):298-9. doi: 10.1016/j.jval.2020.01.008

Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, Dusetzina SB, Wiltshire T. Cost-effectiveness of multigene pharmacogenetic testing in patients with acute coronary syndrome after percutaneous coronary intervention. Value Health. 2020 Jan 1;23(1):61-73. doi: 10.1016/j.jval.2019.08.002

Cawson M, Wolowacz S, Doward L, Sinha A. Health utility estimates for congenital cytomegalovirus disease: conceptual design considerations. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Samuelson T, Singh IP, Katz LJ, Falvey H, Odom D, McSorley D. Effect of iStent inject trabecular micro-bypass on patient-reported outcomes for those with open-angle glaucoma and coexisting cataracts. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Millar (Gildea) L, Stevenson A, Carter K. NICE medical technologies guidance - impact beyond the UK. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Twiss J, Whalley D, Doward L, Balp MM, Brass C, Lopez P, Loeffler J, Cai J, Cryer D, Sanyal AJ, Anstee QM. Psychometric evaluation of NASH-CHECK, a patient-reported outcome measure for Nonalcoholic Steatohepatitis. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Aronsson M, Ling C, Stevenson A, Brodtkorb TH. Submission process and requirements of Nordic health technology assessment (HTA) authorities for hospital drugs - implications for market access strategy. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Pearson I, Stevenson A, Krieger T, Ling C. What is the role of the company evidence submission in National Institute for Health and Care Excellence (NICE) multiple technology appraisals? Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Heyes A, Millar (Gildea) L. Early dialogue with NICE and EUnetHTA: a UK perspective in a politically uncertain era. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Mansfield C, Poulos C, Boeri M, Hauber B. Performance of a comprehension question in discrete-choice experiment surveys (DCE). Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Zhang Y, Herring WL, Martin A, Gunsoy N, Zhang W. Development of a novel economic modeling approach for asthma. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Crawford SR, Morrison R, Doward L. The rise of the social media machine - a review of patient-centered research utilizing social media research methods presented at ISPOR (2010 -2018). Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3). doi: 10.1016/j.jval.2019.09.2281

Gallagher J, Russell L, McAlister M, Brockbank J. Impact of gemtuzumab ozogamicin on the Irish healthcare system. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Rasouliyan L, Martinez D. The effect modification problem: using stratified matching adjusted indirect comparison to evade misleading interpretations of the treatment effect. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Richardson D, Zhan L, Reynolds M, Odom D, McRoy L, Mitra D, Zelnak A, Jones C. Virtual community engagement among women receiving palbociclib for HR+/ HER2- metastatic breast cancer: data from the Madeline study. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(SE).

Ervin C, Thach A, Lee A, Navia B, Evans E, Doward L. Refinement of the treatment preference questionnaire in adults with Parkinson's Disease and off-episodes. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Nov; 22(S3):S756. doi: 10.1016/j.jval.2019.09.1870

Poulos C, Soliman AM, Renz CL, Posner J, Agarwal SK. Patient preferences for endometriosis pain treatments in the United States. Value Health. 2019 Jun;22(6):728-38. doi: 10.1016/j.jval.2018.12.010

Zhang K, Huang SP, Touchette D, Marko-Holguin M, Van Voorhees B. Cost-effectiveness of web-based depression programs for adolescents. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(Suppl 2):S227. doi: 10.1016/j.jval.2019.04.1055

Mauskopf J, Herring W, Zhang Y, Tahami A. The variability in structural assumptions in models estimating the effectiveness of hypothetical disease modifying treatment for Alzheimer's disease. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(Supplement 2):S272.

Ronquest NA, Gould IG, Barnett CL, Mladsi DM. A systematic review of ICER evaluations from 2008 to 2018: recent trends in evaluation process and lessons learned. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(2):S263-4.

Korgaonkar S, Gangan N, Banahan III B, Pittman E, Kirby T, Noble S. Impact of diverse inclusion criteria on assessment of HEDIS Asthma Medication Ratio (AMR) quality measure in Mississippi Medicaid. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 18, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(S1):S358.

Korgaonkar S, Yang Y. Impact of occupational psychosocial risk factors on frequent, severe low back pain in the US working population. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 18, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(S2):S244-5.

Gould I, Herring W, Benninghoff B, Standaert B. Explaining the rotavirus serotype-distribution shift in children after vaccination using a simple transmission model. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(Supplment 2):S202-3.

Gnanasakthy A, Barrett A, Evans E, D'Alessio D, Romano (DeMuro) C. A review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012-2016). Value Health. 2019 Feb;22(2):203-9. doi: 10.1016/j.jval.2018.09.2842

Coles T, Williams V, Dwyer K, Mordin M. Psychometric evaluation of the patient's knee implant performance questionnaire. Value Health. 2018 Nov;21(11):1305-12. doi: 10.1016/j.jval.2018.05.006

Vass C, Ulph F, Georgsson S. Preferences for prenatal and new born screening- a systematic review of discrete choice experiments. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(3):S275.

Dong OM, Lee CR, Wheeler S, Voora D, Dusetzina S, Wiltshire T. A cost-effectiveness analysis of multi-gene pharmacogenetic testing in acute coronary syndrome patients following percutaneous coronary intervention. Presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S6.

Talbird SE, La EM, Carrico J, Poston S, Poirrier J, DeMartino JK, Hogea C. Projected burden of vaccine-preventable diseases in older adults in the United States: impact of population aging. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Supplement 3):S225.

John NM, Gavan S, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(3):S253. doi: 10.1016/j.jval.2018.09.1513

Levine CA, Ansquer V, Kurosky SK. Evaluation of data collection duration in retrospective noninterventional medical record review oncology studies conducted in the United States (US), Canada, United Kingdom (UK), Germany, France and Spain. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S373. doi: 10.1016/j.jval.2018.09.2225

Sluga-O'Callaghan M, Ansquer V, Frugier G, Mai C. Observational studies collecting patient preferences and experiences: regulatory differences across countries in Europe. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S89. doi: 10.1016/j.jval.2018.09.526

Herring W, Gould IG, Casamassima G, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Italy. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.

Herring W, Gould IG, Ruiz L, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Spain. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.

Ling C, Nuabor W, Lyall M, Stevenson A. Review of possible causes of variation in National Institute for Health and Care Excellence (NICE) technology appraisals. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S200.

Soekhai V, de Bekker-Grob EW, Ellis AR, Vass C. Discrete choice experiments in health economics: past, present and future. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(3):S325. doi: 10.1016/j.jval.2018.09.1943

Vass CM, Ulph F, Georgsson S. Preferences for antenatal and neonatal screening: a systematic review of discrete choice experiments. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(S3).

Earnshaw SR. Are we ready to use constrained optimization in health outcomes research? - Editorial. Value Health. 2018 Sep;21(9):1029-30. doi: 10.1016/j.jval.2018.07.004

Harrigan (Zhang) K, Walton SM, Huang SP, Kumar VM, Chapman RH, Atlas SJ, Agboola FO, Ollendorf DA, Touchette DR. Long-term cost effectiveness of valbenazine and deutetrabenazine for tardive dyskinesia. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S184. doi: 10.1016/j.jval.2018.04.1257

Trantham L, Klein AB, Parikh RC, Kurosky S, Zhang Y, Levine CA, Kaye JA. Unresectable, locally advanced, stage III non-small cell lung cancer: real-world clinical characteristics, treatment patterns, and health care resource utilization in Europe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.289

Grimes R, Grant L, Kaur S, Brookes B, Bennett B. Review of frequently implemented patient reported outcomes in current prostate cancer clinical trials. Value Health. 2018 May 1;21(Suppl 1):S225. doi: 10.1016/j.jval.2018.04.1521

Talbird SE, Hogea CS, Meyers J, Carrico J, Buck PO. Cost-effectiveness of a 10-year revaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (TDaP) vaccine among individuals with pre-existing asthma in the United States. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S153. doi: 10.1016/j.jval.2018.04.1062